Registration is open for DDL 2022, which will be the first in-person Drug Delivery to the Lungs meeting since the beginning of the COVID-19 pandemic. The meeting will take place December 7-9 and is expected to attract hundreds of delegates to the Edinburgh International Conference Centre (EICC), with additional delegates able to access the programming online in real … [Read more...] about OINDP specialists to gather in Edinburgh and online for DDL 2022
News
Odyssey Health says Phase 1 results for PRV-002 intranasal therapy for concussion support advancing the nasal powder to Phase 2
Odyssey Health announced that it has completed its Phase 1 study of PRV-002, a novel intranasal synthetic neurosteroid powder formulation that the company is developing for the treatment of concussion, and said that the results support advancing PRV-002 into Phase 2 trials. Odyssey acquired PRV-002 from Prevacus in January 2021. The company recently announced that the … [Read more...] about Odyssey Health says Phase 1 results for PRV-002 intranasal therapy for concussion support advancing the nasal powder to Phase 2
Transpire Bio contracts with Recipharm for development of two more inhaled drugs
After announcing a deal with Recipharm for development of two inhaled drugs (TRB-1 and TRB-2) earlier this year, Transpire Bio says that it has signed an agreement with the CDMO for development of an additional two inhaled products. Under the new agreement, Recipharm will provide development services for Transpire's TRB-3 and TRB-4 inhaled therapeutics for the … [Read more...] about Transpire Bio contracts with Recipharm for development of two more inhaled drugs
Ocugen licenses intranasal COVID-19 vaccine from Washington University in St. Louis
Ocugen announced that it has acquired US, European, and Japanese rights to an intranasal COVID-19 vaccine developed at Washington University in St. Louis. In September 2020, Bharat Biotech announced that it had acquired rights to rights to the Washington University intranasal COVID-19 vaccine outside of the United States, Europe, and Japan, and Bharat recently … [Read more...] about Ocugen licenses intranasal COVID-19 vaccine from Washington University in St. Louis
Qnovia raises $17 million for development of inhaled nicotine replacement therapy
According to Qnovia, which recently changed its name from Respira Technologies, the company has closed a $17 million Series A financing round led by Blue Ledge Capital, with the funds intended to support development of the company's RespiRx inhaled nicotine replacement therapy (NRT). The company said that it intends to submit an IND for the NRT product and anticipates … [Read more...] about Qnovia raises $17 million for development of inhaled nicotine replacement therapy
Wake Forest University School of Medicine gets Alzheimer’s Association grant for Phase 2 trial of intranasal insulin
According to Atrium Health Wake Forest Baptist, Wake Forest University School of Medicine has received a two-year $795,000 grant from the Alzheimer’s Association to support a Phase 2 trial of empagliflozin and intranasal insulin for Alzheimer's disease. The trial will be led by Wake Forest professor Suzanne Craft, who is director of the Alzheimer's Disease Research … [Read more...] about Wake Forest University School of Medicine gets Alzheimer’s Association grant for Phase 2 trial of intranasal insulin
RS BioTherapeutics raises $3 million for development of RSBT-001 inhaled cannabidiolic acid
RS BioTherapeutics, which recently announced positive results from a proof of concept study of its RSBT-001 semi-synthetic cannabidiolic acid (CBDa) in a mouse model, said that the company has raised $3 million in a Seed II funding round. The company says that it is partnered with Synthonics and Marshall University on development of a nebulized formulation of RSBT-001 … [Read more...] about RS BioTherapeutics raises $3 million for development of RSBT-001 inhaled cannabidiolic acid
Vectura gets go-ahead to build new facility for its Inhalation Centre of Excellence
According to inhalation CDMO Vectura, the company been granted planning permission to build a new £58 million, 10,000 sq m facility in Southwest England to house the company's Inhalation Centre of Excellence, with construction expected to be completed in 2025. The company said that it aims for the building on the Bristol & Bath Science Park to receive a BREEAM … [Read more...] about Vectura gets go-ahead to build new facility for its Inhalation Centre of Excellence
Recipharm joins IPAC-RS
CDMO and device maker Recipharm has joined the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS) as a member, the company announced. Recipharm will be represented on the IPAC-RS Board by Head of Commercial – Advanced Delivery Systems Peter Hirst and Director of Inhalation Sciences and Product Development Lei Mao. According to … [Read more...] about Recipharm joins IPAC-RS
Health Canada approves Ryaltris nasal spray for the treatment of seasonal allergic rhinitis
According to Bausch Health and Glenmark, Health Canada has approved Ryaltris olopatadine / mometasone furoate nasal spray for the treatment of seasonal allergic rhinitis in people aged 6 and older. Bausch Health acquired the Canadian rights to Ryaltris in March 2021. Ryaltris has been approved in Australia since December 2019, in Europe since April 2021 and in the US … [Read more...] about Health Canada approves Ryaltris nasal spray for the treatment of seasonal allergic rhinitis